{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:20:17Z","timestamp":1783639217104,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jhepr.2025.101621","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:25:56Z","timestamp":1760073956000},"page":"101621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Liver fibrosis is associated with clinical and economic burden of cardiovascular disease in MASH"],"prefix":"10.1016","volume":"8","author":[{"given":"Kathleen","family":"Corey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-5551","authenticated-orcid":false,"given":"Anurag","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3613-2748","authenticated-orcid":false,"given":"Kamal Kant","family":"Mangla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek Shankar","family":"Chandramouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsan","family":"Shoeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Krarup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2010-8284","authenticated-orcid":false,"given":"Margarida","family":"Augusto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharat","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0502-4381","authenticated-orcid":false,"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2025.101621_bib1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhepr.2025.101621_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jhep.2023.01.026","article-title":"Healthcare and socioeconomic costs of NAFLD: a global framework to navigate the uncertainties","volume":"79","author":"Allen","year":"2023","journal-title":"J Hepatol"},{"issue":"20","key":"10.1016\/j.jhepr.2025.101621_bib3","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.3390\/ijms20205037","article-title":"Development and progression of non-alcoholic fatty liver disease: the role of advanced glycation end products","volume":"20","author":"Fernando","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jhepr.2025.101621_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2025.101621_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhepr.2019.05.009","article-title":"The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: a real-world patient-reported outcomes study","volume":"1","author":"Balp","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2025.101621_bib6","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cgh.2020.06.064","article-title":"Real-world burden of nonalcoholic steatohepatitis","volume":"19","author":"Geier","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.jhepr.2025.101621_bib7","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40273-022-01140-y","article-title":"The economic burden of non-alcoholic steatohepatitis: a systematic review","volume":"40","author":"Witkowski","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jhepr.2025.101621_bib8","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jceh.2022.12.005","article-title":"The growing economic and clinical burden of nonalcoholic steatohepatitis (NASH) in the United States","volume":"13","author":"Younossi","year":"2023","journal-title":"J Clin Exp Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2025.101621_bib9","article-title":"Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study","volume":"2","author":"O'Hara","year":"2020","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101621_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jhepr.2025.101621_bib11","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhepr.2025.101621_bib12","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"issue":"17","key":"10.1016\/j.jhepr.2025.101621_bib13","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101621_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1116861","article-title":"The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease","volume":"10","author":"Finney","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"10.1016\/j.jhepr.2025.101621_bib15","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.jhepr.2025.101621_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11901-020-00530-0","article-title":"Cardiovascular disease in nonalcoholic steatohepatitis: screening and management","volume":"19","author":"Shroff","year":"2020","journal-title":"Curr Hepatol Rep"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101621_bib17","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.jhepr.2025.101621_bib18","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhepr.2025.101621_bib19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","article-title":"Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Sumida","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2025.101621_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.742382","article-title":"Non-alcoholic steatohepatitis pathogenesis, diagnosis, and treatment","volume":"8","author":"Zhu","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.jhepr.2025.101621_bib21","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jfma.2021.07.013","article-title":"The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: a diagnostic or screening tool?","volume":"121","author":"Xu","year":"2022","journal-title":"J Formos Med Assoc"},{"issue":"2","key":"10.1016\/j.jhepr.2025.101621_bib22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.jhepr.2025.101621_bib23","doi-asserted-by":"crossref","first-page":"453","DOI":"10.14309\/ajg.0000000000001606","article-title":"Fibrosis-4 Index can independently predict major adverse cardiovascular events in nonalcoholic fatty liver disease","volume":"117","author":"Vieira Barbosa","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.jhepr.2025.101621_bib24","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","article-title":"Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis","volume":"8","author":"M\u00f3zes","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2025.101621_bib25","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhepr.2025.101621_bib26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhepr.2025.101621_bib27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4291\/wjgp.v8.i2.51","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk","volume":"8","author":"Patil","year":"2017","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"7","key":"10.1016\/j.jhepr.2025.101621_bib28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4254\/wjh.v12.i7.378","article-title":"Non-alcoholic steatohepatitis and the risk of myocardial infarction: a population-based national study","volume":"12","author":"Ghoneim","year":"2020","journal-title":"World J Hepatol"},{"issue":"10","key":"10.1016\/j.jhepr.2025.101621_bib29","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/MCG.0000000000001409","article-title":"Real-world comorbidity burden, health care utilization, and costs of nonalcoholic steatohepatitis patients with advanced liver diseases","volume":"55","author":"Wong","year":"2021","journal-title":"J Clin Gastroenterol"},{"issue":"22","key":"10.1016\/j.jhepr.2025.101621_bib30","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021654","article-title":"Nonalcoholic fatty liver disease and risk of heart failure among medicare beneficiaries","volume":"10","author":"Fudim","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.jhepr.2025.101621_bib31","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.amjmed.2019.09.002","article-title":"Atrial fibrillation and heart failure with preserved ejection fraction in patients with nonalcoholic fatty liver disease","volume":"133","author":"Packer","year":"2020","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.jhepr.2025.101621_bib32","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jacbts.2021.07.010","article-title":"Relationship of nonalcoholic fatty liver disease and heart failure with preserved ejection fraction","volume":"6","author":"Salah","year":"2021","journal-title":"JACC Basic Transl Sci"},{"issue":"11","key":"10.1016\/j.jhepr.2025.101621_bib33","first-page":"1779","article-title":"FIB-4 predicts MACE and cardiovascular mortality in patients with nonalcoholic fatty liver disease","volume":"38","author":"Chew","year":"2022","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jhepr.2025.101621_bib34","article-title":"Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study","volume":"36","author":"Anstee","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1016\/j.jhepr.2025.101621_bib35","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/13696998.2023.2184967","article-title":"Healthcare resource utilization and costs of care in the United States for patients with non-alcoholic steatohepatitis","volume":"26","author":"Tapper","year":"2023","journal-title":"J Med Econ"},{"issue":"4","key":"10.1016\/j.jhepr.2025.101621_bib36","doi-asserted-by":"crossref","first-page":"562","DOI":"10.14309\/ajg.0000000000000484","article-title":"Disease severity is associated with higher healthcare utilization in nonalcoholic steatohepatitis medicare patients","volume":"115","author":"Gordon","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jhepr.2025.101621_bib37","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10198-020-01256-y","article-title":"Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018","volume":"22","author":"Morgan","year":"2021","journal-title":"Eur J Health Econ"},{"issue":"2","key":"10.1016\/j.jhepr.2025.101621_bib38","article-title":"Limitations of non-invasive tests for assessment of liver fibrosis","volume":"2","author":"Patel","year":"2020","journal-title":"JHEP Rep"},{"issue":"9","key":"10.1016\/j.jhepr.2025.101621_bib39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101621_bib40","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.cgh.2009.06.007","article-title":"Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Hossain","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhepr.2025.101621_bib41","first-page":"64","article-title":"Comorbidities and nonalcoholic fatty liver disease: the chicken, the egg, or both?","volume":"36","author":"Glass","year":"2019","journal-title":"Fed Pract"},{"key":"10.1016\/j.jhepr.2025.101621_bib42","article-title":"Are ICD codes reliable for observational studies? Assessing coding consistency for data quality","volume":"10","author":"Nelson","year":"2024","journal-title":"Digit Health"},{"issue":"1","key":"10.1016\/j.jhepr.2025.101621_bib43","article-title":"FIB-4 and APRI for cirrhosis detection in a privately insured national cohort","volume":"6","author":"Parikh","year":"2024","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1016\/j.jhepr.2025.101621_bib44","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.30842","article-title":"Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials","volume":"70","author":"Anstee","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhepr.2025.101621_bib45","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925003039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925003039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T19:44:32Z","timestamp":1778096672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555925003039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2589555925003039"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101621","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver fibrosis is associated with clinical and economic burden of cardiovascular disease in MASH","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101621","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101621"}}